FGD3 and breast cancer: Importantly, a broad ROC Plotter database analysis of RFS across breast cancer patients, unstratified by sub-type, and across all types of chemotherapy, including, but not limited to, doxorubicin and other anthracyclines, demonstrates FGD3’s role as a strong predictive biomarker for chemotherapy response.